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Liposomal Delivery of Demineralized Dentin Matrix
for Dental Tissue Regeneration
Genevieve E. Melling, PhD,1–3 John S. Colombo, PhD,4 Steven J. Avery, PhD,1,3 Wayne Nishio Ayre, PhD,1,3
Samuel L. Evans, PhD,3,5 Rachel J. Waddington, PhD,1,3 and Alastair J. Sloan, PhD1,3
Current dental restorations have short longevity, and consequently, there is a need for novel tissue engineering
strategies that aim to regenerate the dentin-pulp complex. Dentin matrix contains a myriad of bioactive growth
factors and extracellular matrix proteins associated with the recruitment, proliferation, and differentiation of
dental pulp progenitor cells. In this study, we show that demineralized dentin matrix (DDM), from noncarious
dentine, can be encapsulated into liposomes for delivery to dental tissue to promote regeneration. Liposomes
were formulated to encapsulate 0–100mg/mL DDM, lysed with Triton X, and used in vascular endothelial
growth factor (VEGF) and transforming growth factor-b1 (TGF-b1) enzyme-linked immunosorbent assays to
quantify release. The encapsulation efficiencies were calculated to be 25.9% and 28.8% (VEGF/TGF-b1) for
50 mg/mL DDM liposomes and 39% and 146.7% (VEGF/TGF-b1) for 100mg/mL DDM liposomes. All lipo-
some formulations had no cytotoxic effects on a dental pulp stem cell (DPSC) clone, as shown by MTT (3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltertrazolium bromide), Caspase 3/7 assays, and cell counts. The ability of the
liposomes to stimulate DPSC chemotactic recruitment was tested by Boyden chamber chemotaxis assays.
Unloaded liposomes alone stimulated significant progenitor cell recruitment, while DDM-loaded liposomes
further promoted chemotactic recruitment in a dose-dependent manner. DDM liposomes promoted the upre-
gulation of ‘‘osteodentin’’ markers osteocalcin and RUNX2 (Runt-related transcription factor 2) in DPSCs after
9 days of treatment, determined by real-time quantitative PCR. Furthermore, Alizarin Red S staining showed
that unloaded liposomes alone induced biomineralization of DPSCs, and DDM liposomes further increased the
amount of mineralization observed. DDM liposomes were more effective than free DDM (10mg/mL) at acti-
vating recruitment and osteogenic differentiation of DPSC, which are key events in the endogenous repair of the
dentin-pulp complex. The study has highlighted the therapeutic potential of bioactive DDM liposomes in
activating dental tissue repair in vitro, suggesting that liposomal delivery from biomaterials could be a valuable
tool for reparative dentistry and hard-tissue engineering applications.
Keywords: dental tissue engineering, liposomes, demineralized dentin matrix, odontogenesis, dental pulp stem
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Introduction
In response to demineralization from trauma- orcaries-induced acid injury, the dentin-pulp complex can
undergo reparative dentinogenesis. This involves dental
pulp stem cells (DPSCs) being recruited to below the site of
injury and differentiating into odontoblast-like cells,
which produce tertiary/reparative dentin1,2 to protect the
underlying dentin. The mechanisms behind this endogenous
response are not fully delineated; however, the non-
collagenous bioactive protein component of dentin is
thought to play a key role.
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Dentin contains a plethora of growth factors and matrix
proteoglycans, which are involved with the differentiation,
survival, migration, and proliferation of DPSCs and miner-
alization of predentin.3 Studies have highlighted that de-
mineralized dentin matrix (DDM) and soluble whole tooth
extract4 can induce matrix mineralization, in addition to
dental papilla cell5 and DPSC differentiation.6 Our previous
work has highlighted the bioactivity of DDM in dentin and
bone repair, including its ability to promote survival, cell
expansion, osteogenesis, and mineralization in DPSCs6 and
bone marrow mesenchymal stem cells (BMMSCs).7 In ad-
dition, in vivo studies have shown its ability to promote bone
and dentin regeneration.8–10
Despite the capacity of dentin to endogenously regenerate,
the process is overwhelmed in the case of large lesions.
Failure to regenerate dentin results in further exposure of
the vital pulp which, if left untreated, can lead to irre-
versible pulpitis, the treatment for which is endodontic
therapy or whole tooth extraction. In addition to these,
there is an increased risk of abscess formation and syste-
mic infections. Currently, the most common treatment is to
remove the carious dentin and fill with an inert amalgam or
composite material. The current success rates of restorative
dental treatments are variable, with around 50% of restora-
tions failing within 10 years11 and around 25% of endodontic
treatments failing.12 Recent research has aimed to identify
small molecules that could be used in restorative materials to
regenerate the dentin-pulp complex, for example, glycogen
synthase kinase (GSK3) antagonists13 and dentin sialoprotein
(DSP).14 Previous work from our group and others15–17 have
investigated harnessing the bioactivity of DDM in dental
restorations, by testing the use of etching/conditioning agents
to liberate sequestered growth factors within dentin.
Liposomes are amphiphilic lipid vesicles, which self-
assemble in an aqueous environment. They are capable of
protecting their cargo from proteolytic degradation by en-
capsulating drugs both in the lipid bilayer and the aqueous
core, depending on the agent’s hydrophobicity. Liposomes
are excellent tools for controlled, sustained drug delivery18
and have been used to deliver a range of molecules to en-
gineer tissue and stimulate endogenous repair.19 The aim of
this study was to investigate the ability of bioactive lipo-
somes containing DDM to induce a mineralizing phenotype
to promote reparative dentinogenesis.
In this study, phosphatidylserine containing liposomes, a
lipid which has been shown to promote bone mineraliza-
tion,20,21 was used to encapsulate and deliver DDM to a DPSC
clone to promote mineralized tissue repair in vitro.
Materials and Methods
Materials
Phosphatidylcholine from egg yolk (‡99.0%), phospha-
tidylserine from Glycine max (soybean; ‡97%), and cho-
lesterol (‡99.0%). Reagents were, unless otherwise stated,
purchased from Sigma-Aldrich.
Routine cell culture
The primary human dental pulp stem cells (hDPSCs) col-
ony A3 was isolated as previously described,22 and cultured
in a-MEM (containing ribonucleosides and deoxyribonu-
cleosides) supplemented with 10% (v/v) heat-inactivated fetal
bovine serum (ThermoFisher), 4 mM L-glutamine (Thermo-
Fisher), 100 mM L-Ascorbate 2-phosphate, 100 units/mL
penicillin G sodium, 0.1 mg/mL streptomycin sulfate, and
0.25 mg/mL amphotericin.
Preparation of DDM
DDM was prepared using extracted human teeth from in-
formed, consenting patients at the Cardiff University School
of Dentistry, University Hospital Wales. Ethical approval was
granted by the Research Ethics Committee under South East
Wales Tissue Bank approval (12/WA/028). The DDM was
prepared as previously described.7 The lyophilized DDM was
reconstituted in Tris-buffered saline (TBS). Total protein
was measured using a BCA (bicinchoninic acid) assay
(ThermoFisher) and diluted in TBS (0–100 mg/mL).
Preparation of DDM liposomes
Lipids were dissolved in chloroform (ThermoFisher) at
1 mg/mL (w/v) at a ratio of 7:2:1 (w/w) phosphatidylcho-
line:phosphatidylserine:cholesterol. Chloroform was removed
by rotary evaporation (BUCHI Rotavapor R-300) at 332 mbar
for 15 min (water bath at 50C) or until a dry lipid film was
produced. Liposomes were formed by resuspending the lipid
bilayer film in DDM/TBS to a final concentration of 1 mg/mL
(w/v). Liposome batches were then extruded, using a Lipex
extruder (Northern Lipids), through a 100 nm polycarbonate
filter 10 times to produce small unilamellar liposome vesicles
of *100 nm –20 nm. The liposomes were sized by dynamic
light scattering using a Zetasizer Nano ZS (Malvern). Un-
entrapped material was removed by Sephadex G50 column
separation or ultracentrifugation (Sorvall Discovery 100SE
ultracentrifuge) at 100,000 g for 1 h at 4C.23
Assessment of DDM encapsulation into liposomes
Liposomes were separated from unentrapped material
by Sephadex G50 column filtration, as describe in re-
ference 23,23 and were subsequently lysed with 1% (v/v)
Triton X and the amount of vascular endothelial growth factor
(VEGF) and transforming growth factor-b1 (TGF-b1) release
was determined using a commercial enzyme-linked immu-
nosorbent assay (ELISA) (VEGF; R&D Systems and TGF-
b1; ThermoFisher), following manufacturer’s instructions.
Cell treatments
A3 DPSCs (2.2 · 104/cm2) were seeded in six-well pla-
tes and treated with DDM liposomes at concentrations of
0–100 mg/mL (lipid concentration), free DDM (10 mg/mL),
or osteogenic media (supplemented a-MEM plus 10 nM
dexamethasone and 100 mM b-glycerophosphate) for 3, 9,
21, and 35 days. DDM liposomes (DDM concentrations of
0, 1, 10, and 100mg/mL) were ultracentrifuged, resuspended
in supplemented a-MEM and sterile filtered. After treat-
ments, cells were scraped in RLT RNA lysis buffer (Qiagen)
for molecular analysis.
Cytotoxicity assays
A3 DPSCs (1· 104/cm2) were seeded in 96-well plates
(white walled for the Caspase-Glo 3/7 assay; Greiner Bio-
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One). DPSCs were treated with DDM liposomes (0–100mg/
mL DDM) at liposome concentration of 10 ng/mL, for 3, 9,
and 21 days. After 3 days, a Caspase-Glo 3/7 assay (Promega)
was performed by adding 1 volume of Caspase-Glo 3/7
reagent and incubating for 1 h at room temperature before
measuring luminescence. Cell viability was assessed by an
MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltertrazolium
bromide) assay. Twenty-five microliters MTT solution
(5 mg/mL) was added to DPSCs and incubated for 3 h at
37C, media aspirated, and the MTT precipitate solubilized
by the addition of 100 mL dimethyl sulfoxide. Absorbance
was measured at 570 nm, with a reference at 630 nm. Cells
in additional wells were also counted after 3 days.
Boyden transwell recruitment assay
DPSCs (1· 105) were seeded into transwell inserts and
placed on top of media containing liposomes (100 mg/mL).
Recruited cells attached to the transwell inserts were washed
with phosphate-buffered saline (PBS), fixed with 10% (v/v)
formaldehyde, stained with 0.1% (w/v) crystal violet, and
imaged in PBS at 20· magnification on a Nikon Eclipse
TS100 light microscope. Representative images were taken,
and cells were counted using ImageJ image analysis soft-
ware (NIH).
Quantitative real-time PCR
RNA was isolated using the RNeasy Kit (Qiagen), fol-
lowing manufacturer’s instructions. RNA yield was quantified
using a NanoVue spectrophotometer (GE Healthcare). Total
RNA (1mg) was used to generate total complementary DNA
(cDNA) using M-MLV Reverse Transcriptase (Promega).
Osteogenic marker expression was analyzed in a SYBR Green
(Primer Design) quantitative PCR reaction performed on a
QuantStudio 6 Flex Real-Time PCR System (ThermoFisher),
using gene-specific primers for Runt-related transcrip-
tion factor 2 (RUNX2), osteocalcin, and glyceraldehyde
3-phosphate dehydrogenase (GAPDH), as an endogenous
control. The results were analyzed using the DDCT method
according to MIQE guidelines.24,25 The primer sequences
were as follows: GAPDH Forward 5¢-TTCTTTTGCGTC
GCCAGCCGA-3¢, GAPDH Reverse 5¢-GTGACCAGGCG
CCCAATACGA-3¢; RUNX2 Forward 5¢-CCCGTGGCC
TTCAAGGT-3¢, RUNX2 Reverse 5¢-CGTTACCCGCCAT
GACAGTA-3¢; and osteocalcin Forward 5¢-GGCAGCGA
GGTAGTGAAGAG-3¢, osteocalcin Reverse 5¢-CTCACAC
ACCTCCCTCCT-3¢. All primers were validated using total
human cDNA standard curves, and have 90–110% ampli-
fication efficiency.
Alizarin Red S staining
DPSCs were treated with DDM liposomes (100mg/mL)
for 35 days, fixed with 10% (v/v) formaldehyde, and incu-
bated with 2% (w/v) Alizarin Red S (pH 4.2) for 20 min.
After staining, the cells were washed four times with deio-
nized distilled water and images taken at 20· magnification.
Statistical methods
Statistical analysis, where appropriate, was conducted us-
ing a two-tailed paired Student’s t-test comparing two groups.
Data are expressed as mean– standard error of the mean.
Results
DDM was encapsulated into liposomes
for delivery to cells
Liposomes encapsulating 0–100 mg/mL DDM were for-
mulated with an average size of 126.5 – 40 nm (Table 1)
and an average polydispersity index (PDI) of 0.168. There
was no significant ( p > 0.05) variation in size or PDI be-
tween liposomes encapsulating different DDM concentra-
tions. The efficacy of the DDM encapsulation was calculated
by measuring VEGF and TGF-b1 release from lysed lipo-
somes, growth factors known to be highly expressed in
DDM.26,27 One hundred micrograms per milliliter DDM
liposomes encapsulated the greatest amount of VEGF and
TGF-b1, encapsulating 3.1 and 330 pg/mL, respectively
(Table 2). Fifty micrograms per milliliter DDM liposomes
encapsulated 1.06 pg/mL VEGF and 96 pg/mL TGF-b1, and
10mg/mL DDM liposomes encapsulated 0.9 pg/mL VEGF
and 126 pg/mL TGF-b1. The calculated encapsulation effi-
ciency for each growth factor was similar for 50mg/mL DDM
liposomes (25.9% and 28.8% for VEGF and TGF-b1, re-
spectively), however, the encapsulation efficiency varied for
100mg/mL DDM liposomes, with greater efficiency for TGF-
b1 (146.7%) than VEGF (39.0%). Due to the limit of de-
tection of the ELISA Kits, encapsulation efficiencies for 1
and 10mg/mL DDM liposomes were unable to be determined.
All DDM liposomes tested (DDM concentrations of 0, 1,
10, 100 mg/mL; liposome concentrations of 10 ng/mL)
caused no cytotoxic effects on a hDPSCs colony ( p> 0.05),
after 3, 9, or 21 days treatment (Fig. 1A).
DDM liposomes promoted the chemotactic
recruitment of hDPSCs
Next, the effects of DDM liposomes on proliferation,
survival, and recruitment of DPSCs, key events in dentin
repair process, were tested. Liposomal treatments for 72 h
had no significant ( p> 0.05) change in cell proliferation,








Average size – SD (nm) 122.9 – 37.6 124.8– 37 134– 46.1 124.2 – 39.5
PDI 0.164 0.151 0.1825 0.177
A Zetasizer Nano ZS was used to measure the average size and PDI of each batch of liposomes (0–100 mg/mL) by dynamic light
scattering (n = 8 – SD).
DDM, demineralized dentin matrix; PDI, polydispersity index; SD, standard deviation; TBS, Tris-buffered saline.
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assessed by cell counts (Fig. 1B). In line with our previous
findings, free DDM (10mg/mL) treatment for 72 h promoted
the survival of hDPSCs,6 as shown by the reduction in
apoptotic marker Caspase 3/7 (Fig. 1C; p < 0.05) using a
Glo-Caspase 3/7 luciferase assay. However, DPSCs treated
with different concentrations of DDM liposomes had no
significant reduction in Caspase 3 activity ( p > 0.05).
A Boyden transwell chemotaxis assay showed that TBS
and DDM liposomes significantly ( p < 0.0001) promote
chemotactic recruitment of hDPSC (Fig. 2A, B). There was
a dose-dependent increase in DPSC chemotaxis with in-
creasing doses of DDM liposomes over 48 h. TBS liposomes
alone stimulated the chemotaxis of DPSC compared with
the control ( p < 0.0001), but there was further significant
increase in chemotaxis when DPSCs were treated with
100 mg/mL DDM liposomes ( p < 0.01).
DDM liposomes promoted the expression
of osteogenic markers in hDPSCs
The effect of DDM liposomes on promoting osteogenic
differentiation in hDPSCs was investigated via quantita-
tive real-time PCR (qRT-PCR) for ‘‘osteodentin’’ markers,
RUNX2, and osteocalcin, which are early and late markers of
odontogenesis process. After 3 days, there was an increased
trend ( p> 0.05) in RUNX2 expression in DPSCs treated with
free DDM (*2-fold increased) and the higher concentrations
of DDM liposomes treatments (10 and 100mg/mL; * 4- and
1.5-fold increase, respectively; Fig. 3A). This peak of ex-
pression was significantly lost in 10mg/mL ( p< 0.001) and
100mg/mL ( p< 0.0001) DDM liposome-treated hDPSCs at
day 9. The peak of expression was later in cells treated with
free DDM and 1mg/mL DDM liposomes as at day 9, and
Table 2. Demineralized Dentin Matrix was Encapsulated into Liposomes for Delivery
DDM liposomes 0lg/mL (TBS) 10 lg/mL 50lg/mL 100 lg/mL
VEGF
VEGF in free (pg/mL) 0 Undetermined 4.09 – 1.36 7.73 – 0.45
VEGF in intact liposomes (pg/mL) 0.92 – 0.7 3.03 – 3.03 2.28 – 1.2 3.33 – 0.99
VEGF from lysed liposomes (pg/mL) 0 0.91 – 0.91 1.06 – 0.55 3.18 – 1.86
% encapsulation efficiency (VEGF from lysed
liposomes/VEGF in free · 100)
0 Undetermined 25.92% 39.04%
TGF-b1
TGF-b1 in free (pg/mL) 0 Undetermined 333– 98.2 225– 57.2
TGF-b1 in intact liposomes (pg/mL) 0 171 – 90.5 78– 13.1 168– 3
TGF-b1 from lysed liposomes (pg/mL) 0 126 – 78.5 96– 31.3 330– 18.2
% encapsulation efficiency (TGF-b1 from lysed
liposomes/TGF-b1 in free · 100)
0 Undetermined 28.82% 146.66%
0, 10, 50, 100mg/mL DDM liposomes were separated from unentrapped material by Sephadex G50 column filtration, then lysed using 1%
(v/v) Triton-X to release encapsulated cargo, and subsequently used in a VEGF and TGF-b1 enzyme-linked immunosorbent assay, with TBS
and free DDM (10, 50, and 100mg/mL) as controls. From the measured release of growth factor in free DDM and liposomal encapsulated
DDM, encapsulation efficiencies for 10, 50, and 100mg/mL DDM liposomes were calculated. n= 3– standard error of the mean.
TGF-b1, transforming growth factor-b1; VEGF, vascular endothelial growth factor.
FIG. 1. DDM liposomes had no cytotoxic effects in hDPSCs. DPSCs were treated with different concentrations of DDM
liposomes (0–100mg/mL; liposome concentration of 10 mg/mL) for 3, 9, and 21 days and then used in a MTT assay (A) to
assess cell viability. The cells were then counted with a hemocytometer (B) or used in a Caspase-Glo 3/7 assay (C), which
measures apoptotic caspase-3 activity using a bioluminescence substrate. n = 3 – SEM significance is indicated by *p< 0.05
and **p< 0.01 (unpaired Student’s t-test compared to control). DDM, demineralized dentin matrix; DPSCs, dental pulp
stem cells; hDPSCs, human dental pulp stem cells; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltertrazolium bromide;
RLU, relative luminescence unit; SEM, standard error of the mean; TBS, Tris-buffered saline.
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there was a *4-fold increase in RUNX2 expression com-
pared with day 3 control ( p> 0.05). Of note, TBS liposomes
induced significant ( p< 0.05) *1.2-fold increase in RUNX2
expression at day 3, which was lost at day 9.
Free DDM and 1 mg/mL DDM liposomes caused a
*12-fold ( p < 0.05) and *26-fold ( p > 0.05) increase in
osteocalcin expression, respectively, after 9 days (Fig. 3B).
In these conditions, the relative expression of osteocalcin
decreased after 21 days of treatment. For the higher DDM
liposome concentrations (10 and 100mg/mL), the levels of
osteocalcin transcript significantly increased after 21 days
of treatment ( p < 0.05), compared with 9 days. Again, TBS
liposomes caused a significant ( p < 0.001) increase in os-
teocalcin messenger RNA levels after 21 days of culture,
compared with day 9.
DDM liposomes induced mineralization of hDPSCs
Mineralization, a marker of late osteogenesis, was exam-
ined in hDPSCs treated with DDM liposomes. After 35 days,
there was increased Alizarin Red S staining in hDPSC treated
with DDM liposomes (10 and 100mg/mL DDM) compared
with untreated, osteogenic media and free DDM (10mg/mL)
controls (Fig. 3C). Interestingly, TBS liposomes also in-
creased DPSC mineralization compared with the untreated
controls.
Discussion
Dentin contains a ‘‘cocktail’’ of factors,3 including
VEGF, fibroblast growth factor, epidermal growth factor,26
matrix metalloproteinases, and members of TGF-b super-
family (TGF-b 1, 2, 3,27 bone morphogenetic protein 2, 4,
and 7), which synergistically coordinate dentin repair, re-
cruitment, and osteo-/odontoinduction of stem cells.5,28,29 In
addition, small leucine-rich proteoglycans, biglycan and
decorin,30 and dentin-specific molecules such as DSP14 and
dentin phosphoprotein (DMP-1) have been shown to con-
tribute toward DDM bioactivity. In line with this, we found,
FIG. 2. DDM liposomes pro-
moted the chemotaxis of hDPSCs
in a dose-dependent manner.
DPSCs were seeded into Boyden
transwell inserts, placed on lipo-
some treatments (100mg/mL),
SFM, free DDM (10 mg/mL), or
control (basal a-MEM) and al-
lowed to pass through a 0.8 mm
membrane for 48 h. Membranes
were then fixed and stained with
0.1% (w/v) crystal violet, respec-
tive photos were taken (B) and re-
cruited cells counted (A).
n = 3– SEM significance indicated
by *p < 0.05, **p < 0.01, and
****p < 0.0001 (unpaired Student’s
t-test compared to control). SFM,
serum-free media. Color images
available online at www.liebertpub
.com/tea
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when liposomes were used to deliver DDM to a human
DPSC clone, they stimulated chemotactic recruitment,
odontogenic differentiation, and biomineralization.
In vivo, for dentin regeneration to occur, DPSCs are first
required to migrate toward tertiary dentin to the site of in-
jury, where they subsequently proliferate and provide a
source of progenitors for odontogenic differentiation to
produce new dentin.1 In this study, biocompatible TBS
phosphatidylserine liposomes were sufficient to stimulate
the chemotactic recruitment of hDPSCs, and DDM liposomes
further promoted DPSCs chemotaxis in a dose-dependent
manner, suggesting that DDM liposomes are releasing their
cargo to allow paracrine signaling. In this way, DDM lipo-
somes are initiating the first crucial events in dentin repair.
A previous study from our group7 showed that only low
DDM doses (0.1 mg/mL) were able to promote migration of
BMMSC, and higher doses (1–10 mg/mL) were inhibitory to
migration. Similarly, several studies have demonstrated that
low doses of DDM promote cellular wound healing through
stimulating migration, differentiation,29,31 and angiogene-
sis,32 however, higher doses were found to have an inhibi-
tory effect. In this study, 10 mg/mL DDM promoted hDPSC
migration and, despite being a smaller dose according to
encapsulation efficacies, DDM liposomes promoted more
migration than free DDM, we postulate that this is due to the
slow, consistent release of multiple chemokines having a
greater combined effect.
Liposomal delivery of growth factors has been used to
promote wound healing, cardiac, cartilage, and bone re-
generation.33–36 Many studies have profiled drug retention
in liposomes over time and demonstrated that liposomes
have a slower release rate of the encapsulated drug/growth
factor compared to free drug.37–39 Giannoni and Hunziker35
observed that the rate of TGF-b1 release from liposomes in
FIG. 3. DDM liposomes promoted the osteogenic differentiation of hDPSC progenitor cells. DPSCs were treated with
DDM liposomes (0–100 mg/mL DDM, 10 mg/mL liposome), free 10mg/mL, or control for DDM for 3, 9, and 21 days. qRT-
PCR was performed using primers to amplify RUNX2, an early osteodentine marker, at days 3 and 9 (A) and osteocalcin, a
late osteodentine marker, at days 9 and 21 (B), their expression compared to endogenous control GAPDH. The data are
shown relative to day 3 control (A) and day 9 control (B). After 35 days of treatment, the amount of calcium deposition was
assessed by Alizarin Red S staining using 2% (w/v) Alizarin Red S, cultures treated with 100mg/mL DDM liposomes, and
representative pictures taken at 20· magnification (C). n = 3– SEM significance indicated by *p < 0.05, **p < 0.01,
***p< 0.001, and ****p < 0.0001 (unpaired Student’s t-test compared to control). GAPDH, glyceraldehyde 3-phosphate
dehydrogenase; qRT-PCR, quantitative real-time PCR; RUNX2, Runt-related transcription factor 2. Color images available
online at www.liebertpub.com/tea
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fibrin clots was lower compared to free drug release over an
initial 5-day period. A body of research40,41 has demon-
strated that a sustained release of growth factors from bio-
materials is more effective at producing a cellular response
and driving mineralized tissue repair than an initial burst.
Likewise, the sustained release of DDM from liposomes
within a material is proposed to be more successful than the
delivery of individual growth factors due to the synergistic
multi-osteoinductive growth factors and matricellular com-
ponents, which can sequester bioactivity and orchestrate
endogenous dentin-pulp complex repair.
Encapsulation of DDM into liposomes allows for a sus-
tained, controlled, local delivery42 of DDM over time, re-
ducing the need for high doses of free DDM, which has a
lengthy production time and uses a limited resource of
noncarious human teeth. Research has recently shown that
whole DDM is more effective at driving bone repair than
individual fractions separated by heparin affinity chroma-
tography,7 thus, a proportion of the entire DDM may be
necessary to be encapsulated to drive full dental repair. To
establish the amount of DDM encapsulation and therefore
the dose of DDM administered to cells, single growth factor
ELISAs were used for VEGF and TGF-b1. This highlighted
that the liposomes are likely to differentially encapsulate
individual constituents of DDM, as TGF-b1 had a much
greater encapsulation efficiency at 100mg/mL than VEGF
(146.7% compared to 39.0%). Therefore, it is difficult to
assess the exact delivery of DDM constituents to cells using
liposomal carriers. Further work is needed to assess the
exact encapsulation in DDM liposomes and to delineate how
DDM liposomes elicit their response, for example, through
cargo release or uptake into DPSCs. The migration data
suggest DDM release from liposomes, however, we cannot
rule out that liposomes may enter cells by endocytosis or
membrane fusion, as many have previously shown43,44 to
deliver DDM components to produce the observed miner-
alizing phenotype.
We observed an increase in mineralization with control
(TBS) liposomes, which was further increased when lipo-
somes were loaded with bioactive DDM, suggesting that
DDM liposomes are inducing differentiation. The biomi-
neralization observed with control liposomes was likely to
be the result of phosphatidylserine in the liposomal formu-
lation. Phosphatidylserine is known to bind calcium ions to
promote mineralization,45 and has previously been used to
coat prosthetic implants, which has promoted osteoblast
attachment, mineralization, and osseointegration in both
in vitro and in vivo experiments.46,47 Control liposomes also
promoted the expression of osteodentin markers, and che-
motaxis, suggesting that the phosphatidylserine containing
liposomal carrier is beneficial for delivering DDM for pro-
moting mineralized tissue.
Data presented in this study suggest that liposomes are
highly efficient at delivering low, sustained doses of DDM
that are required for stimulating dental tissue repair. The
dentin regeneration seen in vivo, referred to as tertiary
dentin, has been reported to be histologically and bio-
chemically similar to bone.48 In addition, some proteins that
are classically considered as dentin-specific are down-
regulated in tertiary dentin (DSP and DMP-1).49 This study
assessed therefore osteodentin markers RUNX2 and osteo-
calcin in response to DDM liposomes. RUNX2 is a key
transcription factor involved in early osteogenesis and
odontogenesis, but it is downregulated in terminal differ-
entiation.50,51 This trend was observed in DPSCs treated
with high concentrations of DDM liposomes (10 and 100 mg/
mL DDM), where RUNX2 expression was upregulated at
day 3, but significantly downregulated at day 9. Osteocalcin
is an extracellular dentin and bone matrix protein recog-
nized as a late stage marker of odontoblast and osteoblast
differentiation.52,53 Higher concentrations of DDM lipo-
somes and free DDM induced osteocalcin expression after
21 days. Taken together, the analysis of markers suggests
that DPSCs treated with DDM liposomes are undergoing
differentiation into odontoblast-like cells, highlighting the
potential therapeutic use of these liposomes in regenerative
dentinogenesis.
Bioactive DDM liposomes could be applied in various
biomaterials for hard-tissue engineering purposes. Members
of our group have previously optimized a highly efficient
liposomal drug delivery system in bone cements,54 inte-
grating liposomes in polymethyl methacrylate bone cements
with minimal integral artefacts. This study has particularly
highlighted the potential use of these liposomes in restor-
ative dental materials, for example, liposomes could be re-
leased from glass ionomer cements or modified hydrogels
(Mourtas et al.55) to harness the tooth’s natural repair
mechanisms. Alternatively, the liposomes could even be
directly applied to the pulp during a pulpotomy to enhance
pulp dentin regeneration.
This work has shown that bioactive dentin growth fac-
tors and matrices can be incorporated and released from
liposomes to recruit and differentiate DPSC, promoting
dentinogenesis in vitro. The enhancement of dentin reminer-
alization and activation of local DPSCs would, in turn, delay
the progression of dental disease and thereby improve the
longevity of dental restorations.
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